Zhi Tong Cai Jing·2025-10-31 02:21Core Viewpoint - Fosun Pharma's stock price increased by approximately 4% during trading, reflecting positive market sentiment following the release of its financial results for the nine months ending September 30, 2025, which showed a mixed performance in revenue and profit [1] Financial Performance - The company reported a revenue of 29.393 billion yuan, a decrease of 4.91% year-on-year [1] - Net profit attributable to shareholders was 2.523 billion yuan, an increase of 25.5% year-on-year [1] - Basic earnings per share stood at 0.95 yuan [1] Key Drivers of Performance - The increase in net profit was primarily attributed to gains from the sale of remaining equity in United Family Healthcare and other non-core assets [1] - The company is actively advancing the launch of innovative products, with several new drug approvals in September, including a new indication for the small molecule CDK4/6 inhibitor and approvals for other products in the U.S. and EU [1] Future Outlook - Analysts believe that the ongoing launch of innovative drugs will contribute to a recovery in revenue for the company [1]